Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PLG | P00747 | 1/20 | 0.54 |
| ▸ | PLAT | P00750 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.48 |
| ▸ | GABRD | O14764 | 2/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.48 |
| ▸ | GABRE | P78334 | 2/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7817617 | 1.00 | LMNA (0.54) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL15139817 | 1.00 | LMNA (0.54) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL5083510 | 0.92 | LMNA (0.48) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL6269799 | 0.89 | KDM4E (0.46) | LMNAPLGPLATTSHRGABRP | |
| SCHEMBL6273385 | 0.88 | LMNA (0.45) | LMNAPLGPLATTSHRGABRP | |
| Cyclopropane Carboxylic Acid SCHEMBL630476 | 0.88 | LMNA (0.59) | LMNAPLGPLATTSHRGABRP | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL8743189 | 0.88 | SMN1; SMN2 (0.46) | LMNAPLGPLATTSHRSMN1; SMN2 | |
| SCHEMBL9797557 | 0.87 | SMN1; SMN2 (0.50) | LMNAPLGPLATTSHRSMN1; SMN2 | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL6927157 | 0.87 | SMN1; SMN2 (0.50) | LMNAPLGPLATTSHRSMN1; SMN2 | |
| Cyclopropanecarboxylic Acid Amide SCHEMBL5661 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0567967-B1 | Tritium-labelled fibrinogen-receptor-antagonists, their use and their production | THOMAE GMBH DR K (DE) | 1996-07-10 | — | — | EP | claimed |
| EP-3889154-A1 | HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| EP-3814326-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-05-05 | — | — | EP | disclosed |
| CN-109456210-B | Hypocrellin peri-and 2-amino-substituted derivative and preparation method and application thereof | 中国科学院理化技术研究所 | 2020-09-25 | — | — | CN | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
| EP-3168256-B1 | EYEWEAR MATERIAL COMPRISING A POLYURETHANE RESIN, EYEWEAR FRAME AND LENS | MITSUI CHEMICALS INC (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2626344-B1 | METHOD FOR PRODUCING TRANS-1,4-BIS(AMINOMETHYL)CYCLOHEXANE | MITSUI CHEMICALS INC (JP) | 2019-05-15 | — | — | EP | disclosed |
| EP-3037411-B1 | 1,4-BIS(ISOCYANATOMETHYL)CYCLOHEXANE, POLYISOCYANATE COMPOSITION, POLYURETHANE RESIN, MOLDED ARTICLE, EYEWEAR MATERIAL, EYEWEAR FRAME AND LENS | MITSUI CHEMICALS INC (JP) | 2019-03-27 | — | — | EP | disclosed |
| EP-2626343-B1 | METHOD FOR PRODUCING BIS(AMINOMETHYL)CYCLOHEXANES | MITSUI CHEMICALS INC (JP) | 2018-12-26 | — | — | EP | disclosed |
| EP-2026798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007132119-A1 | IN SITU OR ONE-POT HYDROGENATION AND REDUCTIVE AMINATION METHOD | PPG-SIPSY (FR) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007125048-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
| EP-0889041-B1 | NOVEL IRIDOID DERIVATIVES AND NEOVASCULARIZATION INHIBITORS CONTAINING THE SAME AS ACTIVE INGREDIENT | TSUMURA & CO (JP) | 2002-07-24 | — | — | EP | disclosed |
| EP-0798298-B1 | THIAZOLIDINONE OR OXAZOLIDINONE DERIVATIVES TO TREAT ANGINA PECTORIS OR COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENT | SANKYO CO (JP) | 2001-08-08 | — | — | EP | disclosed |
| EP-0889041-A1 | NOVEL IRIDOID DERIVATIVES AND NEOVASCULARIZATION INHIBITORS CONTAINING THE SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1999-01-07 | — | — | EP | disclosed |
| US-5843973-A | Thiazolidinone compounds and composition for angina pectoris comprising the compounds as an active ingredient | SANKYO COMPANY, LIMITED (JP) | 1998-12-01 | — | — | US | disclosed |
| US-5677466-A | TESTING USING A AMIDINOPHENYL CONTAINING COMPOUND | DR. KARL THOMAE, GMBH (DE) | 1997-10-14 | — | — | US | disclosed |
| EP-0798298-A1 | THIAZOLIDINONE COMPOUNDS OR ANGINA PECTORIS REMEDY OR PREVENTIVE CONTAINING THE SAME AS ACTIVE INGREDIENT | SANKYO COMPANY LIMITED (JP) | 1997-10-01 | — | — | EP | disclosed |
| US-4259258-A | Preparation of bis-n-chloramides of cycloaliphatic carboxylic acids | AKZONA INCORPORATED (US) | 1981-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | LMNA 3609/4885PLG 4276/4885PLAT 1128/4885 |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | LMNA 2722/4885PLG 2703/4885PLAT 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.